FibroBiologics, Inc. (FBLG) AI Stock Analysis

• Market Cap: $18.67M
• Dividend Yield: N/A
• Average Volume (3M): 978.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 67,594,720
• 10 Day Avg. Volume: 1,423,641
• 30 Day Avg. Volume: 978,931
• PEG Ratio: -0.02
• Price to Book (P/B): 1.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.60
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -19.56
• Enterprise Value/Ebitda: -0.52
• 1Y Price Target: $2.75
• Price Target Upside: 882.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.27 ▼(-2.14% Downside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is weighed down primarily by weak financial performance (no revenue, widening losses, and increasing cash burn), indicating continued reliance on external financing. Technicals also reflect a weak trend with the stock below key moving averages. Corporate events add risk due to ongoing Nasdaq delisting uncertainty, while valuation signals are limited by negative earnings and no dividend.

Positive Factors

Improved balance sheet

Reducing debt and restoring positive equity materially lowers near-term solvency risk and improves negotiating leverage with lenders or partners. This stronger capital base provides a firmer platform to fund clinical programs and extend runway versus prior years, easing immediate refinancing pressure.

Capital-structure flexibility

Board-authorized reverse-split authority and approved warrant issuances give management durable tools to manage share count, comply with listing rules, and complete previously arranged financings. Structural flexibility supports orderly capital raises and honoring warrant exercises without needing ad hoc approvals.

Focused R&D platform

A specialized fibroblast-based therapeutic platform targets regenerative-medicine niches where cell therapies can offer differentiated mechanisms. Deep domain focus can create technical barriers and long-term IP value if clinical programs advance, underpinning potential durable competitive advantage in a high-barrier industry.

Negative Factors

Pre-revenue and widening losses

Absent product revenue and materially widening losses mean operating leverage is negative and the company cannot self-fund development. Persistent deficits increase the probability of future dilutive financings and place program continuity at risk unless clinical milestones attract non-dilutive funding or partners.

Nasdaq listing and governance risk

Ongoing listing noncompliance and a pending hearings panel are structural governance risks that can restrict access to institutional capital, raise refinancing costs, and force remedial actions (reverse split, additional dilution, or listing move). This overhang materially affects long-term investor base and financing options.

High cash burn vs. small team

Very high annual cash burn relative to a small headcount implies reliance on outsourced partners and external funding to run trials. Limited internal capacity can slow program execution and increase execution risk if financing lapses, making clinical progress sensitive to capital availability and partner arrangements.

FibroBiologics, Inc. Business Overview & Revenue Model

Company Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

How the Company Makes Money

null

FibroBiologics, Inc. Financial Statement Overview

Summary

Pre-revenue profile with no revenue reported (2020–2025) and materially widening losses (net income to -$18.6M in 2025) alongside worsening operating/free cash flow (OCF -$16.4M; FCF -$16.7M in 2025). Balance sheet improved in 2025 with sharply lower debt ($2.4M vs $10.6M in 2024) and positive equity (~$6.2M), but the business remains highly dependent on external funding due to accelerating cash burn.

Income Statement

The company reports no revenue across 2020–2025, consistent with an early-stage biotechnology profile. Losses have widened materially, with net income moving from -$1.2M (2020) to -$18.6M (2025), and EBIT also deteriorating (to -$16.6M in 2025). While R&D-driven investment can be expected in this industry, the absence of revenue and accelerating losses keep profitability and operating leverage weak.

Balance Sheet

Balance sheet risk has improved versus 2024: total debt fell to $2.4M in 2025 from $10.6M in 2024, and debt-to-equity improved to ~0.39 from ~3.86. Equity is positive in 2023–2025 (2025 equity ~$6.2M), a meaningful improvement from negative equity in 2021–2022, and total assets are ~$9.6M in 2025. However, returns remain deeply negative given ongoing losses, and the company’s financial position is still sensitive to continued cash burn and funding needs.

Cash Flow

Cash generation remains weak with operating cash flow negative each year and worsening to -$16.4M in 2025 (from -$11.9M in 2024). Free cash flow is also negative and declined to -$16.7M in 2025, with a slight additional contraction versus 2024. While free cash flow roughly tracks net losses (free cash flow to net income ~1.02 in 2025), the overall trajectory indicates increasing cash burn, implying reliance on external financing to sustain operations.

Breakdown	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-832.00K	0.00	0.00	0.00	0.00
EBITDA	-17.61M	-10.57M	-15.90M	-4.37M	-1.58M
Net Income	-18.65M	-11.16M	-16.48M	-5.12M	-1.58M
Balance Sheet
Total Assets	9.62M	16.45M	11.82M	4.82M	468.00K
Cash, Cash Equivalents and Short-Term Investments	4.89M	13.98M	9.16M	2.27M	407.00K
Total Debt	2.41M	10.55M	1.75M	7.52M	1.30M
Total Liabilities	3.46M	13.71M	10.57M	8.82M	1.76M
Stockholders Equity	6.16M	2.73M	1.25M	-4.00M	-1.29M
Cash Flow
Free Cash Flow	-16.66M	-12.09M	-6.90M	-4.07M	-1.41M
Operating Cash Flow	-16.39M	-11.90M	-6.40M	-4.07M	-1.41M
Investing Cash Flow	-262.00K	-184.00K	-495.00K	0.00	0.00
Financing Cash Flow	7.57M	16.91M	13.79M	5.92M	1.82M

FibroBiologics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.31, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 42.19 is Neutral, neither overbought nor oversold. The STOCH value of 6.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBLG.

FibroBiologics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	48 Neutral	$12.64M	-3.82	-22.03%	―	-41.76%	87.36%
CRIS	45 Neutral	$12.25M	-0.84	354.21%	―	13.56%	52.92%
FBLG	44 Neutral	$18.67M	-0.77	-1292.87%	―	―	18.47%
PCSA	41 Neutral	$7.16M	-0.66	-301.42%	―	―	72.88%
SYBX	40 Underperform	$7.84M	-13.72	-27.54%	―	-100.00%	93.62%

FibroBiologics, Inc. Corporate Events

FibroBiologics Updates CFO Compensation to Support Leadership

On March 4, 2026, FibroBiologics, Inc. disclosed that its Compensation Committee approved an increase in the annual base salary for Chief Financial Officer Jason D. Davis to $400,000, effective January 1, 2026. The decision, which keeps Davis’s target non-equity incentive compensation at 40% of base salary, reflects the company’s ongoing approach to executive remuneration and may signal recognition of his role in its financial and strategic management.

The adjustment to the CFO’s compensation structure underscores FibroBiologics’ emphasis on aligning executive pay with corporate performance and responsibilities. While the move is focused on internal governance, it could be viewed by investors and other stakeholders as an indication of the company’s commitment to retaining key leadership as it advances its business objectives in the competitive biotech sector.

The most recent analyst rating on (FBLG) stock is a Hold with a $0.41 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Shareholders Approve Reverse Split, Warrant Issuances

FibroBiologics, Inc. reported that at a special meeting of stockholders held on February 20, 2026, investors approved an amendment to its certificate of incorporation authorizing the board to implement a reverse stock split in a range of 1-for-5 to 1-for-30 at its discretion within one year. Stockholders also approved multiple issuances of common shares underlying outstanding warrants tied to prior securities purchase agreements from November and December 2025, as well as related bank engagement warrants.

These approvals give the board flexibility to manage FibroBiologics’ capital structure and share price, while clearing the way for the company to honor warrant exercises and secure previously arranged financing under Nasdaq’s shareholder approval rules. Investors additionally authorized potential adjournments of the special meeting to solicit more votes if needed, signaling broad support for the company’s financing and capital-management strategy.

The most recent analyst rating on (FBLG) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Faces Nasdaq Delisting Review After Noncompliance

On August 4, 2025, FibroBiologics, Inc. was notified by Nasdaq that its market value of listed securities had fallen below the required $35 million minimum for 30 consecutive trading days, triggering a 180-day grace period through February 2, 2026, to regain compliance. On February 3, 2026, Nasdaq staff issued a formal notice that the company’s continued non-compliance with the market value rule now constitutes an additional basis for delisting, alongside a previously disclosed bid price deficiency. The matter is currently before a Nasdaq Hearings Panel, which will review FibroBiologics’ plan to restore compliance, and the company’s stock will remain listed and trading at least until the panel issues a decision and any potential extension expires. As part of its efforts, FibroBiologics filed definitive proxy materials on December 29, 2025, seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, although there is no assurance the company will obtain an extension or successfully meet the listing standards, leaving investors facing ongoing uncertainty over the firm’s Nasdaq listing status.

The most recent analyst rating on (FBLG) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split

On July 1, 2025, FibroBiologics, Inc. was notified by Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive trading days, triggering a 180-day grace period, through December 29, 2025, to regain compliance. After the company failed to meet the requirement by that deadline, Nasdaq staff notified FibroBiologics on December 30, 2025, of its intention to delist the stock unless the company requested a hearing, which FibroBiologics plans to do, temporarily staying any suspension or delisting. The company is monitoring its share price and, as part of its efforts to regain compliance, filed definitive proxy materials on December 29, 2025 seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, though there is no assurance it will secure an extension or that these measures will succeed, leaving its Nasdaq listing status uncertain for investors.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.